When common medications produce uncommon adverse effects
Atorvastatin has an established role in reducing cardiovascular morbidity and mortality and is generally considered safe. However, this case reminds clinicians that even widely prescribed medications may rarely produce unexpected neurological or otological complications.
A 45-year-old Ethiopian woman developed bilateral tinnitus followed by progressive, symmetric sensorineural hearing loss approximately three weeks after starting atorvastatin 40 mg daily. She had no history of noise exposure, chronic ear disease, head trauma, or exposure to other ototoxic medications. Audiometry confirmed bilateral moderate sensorineural hearing loss, while evaluation excluded alternative metabolic, infectious, and autoimmune causes.
The temporal relationship between drug initiation and symptom onset prompted discontinuation of atorvastatin. Improvement was already evident after one week, with complete normalization of hearing thresholds and full resolution of tinnitus by one month. Subsequent treatment with rosuvastatin was well tolerated, with no recurrence during six months of follow-up. The authors further supported causality using the Naranjo adverse drug reaction probability scale, which indicated a probable drug-related adverse event.
Although isolated reports of statin-associated hearing loss exist, this case is notable because complete recovery was documented by serial audiometry. It contrasts with previously published irreversible cases and suggests that the duration of drug exposure and the speed of recognition may influence clinical outcome.
The report reinforces several practical messages for clinicians. New-onset tinnitus or hearing loss in patients receiving atorvastatin should prompt careful medication review alongside the standard evaluation for sensorineural hearing loss. Early discontinuation of the suspected offending agent may prevent permanent auditory impairment while allowing alternative lipid-lowering therapy to be instituted.
Clinical Take-Home Message
Although atorvastatin-associated sensorineural hearing loss appears to be exceedingly rare, clinicians should remain alert to new auditory symptoms developing soon after statin initiation. Prompt recognition, audiometric assessment, and timely withdrawal of the suspected medication may allow complete recovery and prevent irreversible hearing loss.
Journal of Medical Case Reports is the world's first international, PubMed-listed medical journal devoted to publishing case reports from all medical disciplines and will consider any original case report that expands the field of general medical knowledge, and original research relating to case reports. The journal is open access and strongly endorses the CARE guidelines for case reports, requiring authors to submit populated CARE checklists with submissions to improve transparency in reporting.